Key Product Details

Species Reactivity

Human, Mouse

Applications

CyTOF-ready, Flow Cytometry, Immunohistochemistry, Immunohistochemistry-Frozen, Immunohistochemistry-Paraffin, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG2 Clone # MM0491-8F24

Format

Azide and BSA Free

Concentration

LYOPH mg/ml

View all NKp46/NCR1 Antibodies »

Product Specifications

Immunogen

Human recombinant NKp46/NCR1

Reactivity Notes

Mouse reactivity reported in scientific literature (PMID: 29078276).

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2

Scientific Data Images for NKp46/NCR1 Antibody (MM0491-8F24) - Azide and BSA Free

Immunohistochemistry-Paraffin: NKp46/NCR1 Antibody (MM0491-8F24) [NBP2-11820] - Human lymph node metastatsis section stained for Nkp46, antibody dilution 1:70, incubated O/N at 4C. Antigen retrieval in citrate buffer. Image from verified customer review.
Immunohistochemistry-Frozen: NKp46/NCR1 Antibody (MM0491-8F24) [NBP2-11820] - Mouse anti human NKp46 in diseased human liver tissues (frozen section).

Applications for NKp46/NCR1 Antibody (MM0491-8F24) - Azide and BSA Free

Application
Recommended Usage

Flow Cytometry

1:50-1:100

Immunohistochemistry

1:10-1:500

Immunohistochemistry-Frozen

1:20-1:100

Western Blot

1:500-1:1000
Application Notes
This antibody is Cytof ready.

Reviewed Applications

Read 1 review rated 4 using NBP2-11820 in the following applications:

Formulation, Preparation, and Storage

Purification

Protein G purified

Reconstitution

Reconstitute with sterilized PBS to a final concentration of 0.5 mg/ml.

Formulation

Lyophilized from a 0.2 um filtered solution in PBS. 0.025 mg size is provided in liquid form, PBS

Format

Azide and BSA Free

Preservative

No Preservative

Concentration

LYOPH mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.

Background: NKp46/NCR1

NKp46 (also known as natural cytotoxicity receptor 1, NCR1), is a ~46 kDa Type 1 transmembrane protein and a member of the immunoglobulin superfamily (1). NKp46 is highly conserved in mammals and can be characterized by two extracellular C2-type Ig-like domains followed by a stalk region (1). NKp46 is expressed by activated and resting natural killer (NK) cells, innate lymphoid cell (ILC) 1, and a small population of T lymphocytes (1). NKp46, along with NKp30 and NKp44, are activating receptors that have been collectively termed the natural cytotoxicity receptors (NCRs) (2). The NKp46 and NKp30 receptors play a major role in triggering some of the key lytic activities of NK cells (2). NKp46 is the only cytotoxicity receptor with a mouse orthologue, known as mNKp46 (2).

NKp46 plays a critical role in the NK-cell lysis of allogenic, autologous, and xenogeneic cells (3). Activation of NKp46 signaling is mediated via its association with immunoreceptor tyrosine-based activation motif (ITAM) bearing molecules CD3zeta and FcRgamma (3). Upon receptor-engagement NK-cell cytotoxic activity and cytokine release occurs (3). This NKp46 signaling can be blocked with anti-NKp46 monoclonal antibody mediated cross-linking which causes calcium release and interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) secretion (3). NKp46 recognizes multiple ligands presented on tumor cells or pathogens and infected cells including influenza virus hemagglutinin and the parainfluenza virus hemagglutinin neuraminidase (2). Additional ligands for the NKp46 receptor include heparan sulfate (HS) glycosaminoglycans (GAGs), hemagglutinin of human vaccina virus, and vimentin expressed on cells infected with Mycobacterium tuberculosis (3).

NKp46 and its NCR counterparts have shown to be successful targets for cancer immunotherapy. More specifically, human and mouse NKp46 has shown promise in virotherapy due to its ability to stimulate NK cell activation by binding to reovirus sigma1 protein in a sialic acid-dependent manner (3). Another approach for NKp46 in cancer immunotherapy is through the use of NCR based chimeric antigen receptors (CARs). In this therapy, NCR1 supplied human T cells with anti-tumor properties via cytokine secretion, upregulation of activation markers, improved expansion, and cytotoxicity in both mouse and in vitro models (3).

References

1. Barrow, A. D., Martin, C. J., & Colonna, M. (2019). The Natural Cytotoxicity Receptors in Health and Disease. Frontiers in immunology, 10, 909. https://doi.org/10.3389/fimmu.2019.00909

2. Mandelboim, O., & Porgador, A. (2001). NKp46. The international journal of biochemistry & cell biology, 33(12), 1147-1150. https://doi.org/10.1016/S1357-2725(01)00078-4

3. Barrow, A. D., Martin, C. J., & Colonna, M. (2019). The Natural Cytotoxicity Receptors in Health and Disease. Frontiers in immunology, 10, 909. https://doi.org/10.3389/fimmu.2019.00909

Alternate Names

CD335, Ly94, MAR-1, NCR1

Gene Symbol

NCR1

UniProt

AAH64806

Additional NKp46/NCR1 Products

Product Documents for NKp46/NCR1 Antibody (MM0491-8F24) - Azide and BSA Free

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for NKp46/NCR1 Antibody (MM0491-8F24) - Azide and BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.